Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bard set for Gore money soon as Q3 "solid"

This article was originally published in Clinica

Executive Summary

CR Bard had a “solid” third quarter, beating analyst expectations across all divisions and seeing margin expansion, noted Jefferies’ Raj Denhoy. Standout performances came in its vascular and surgical divisions, which saw sales of $209.9m (+4% year-on-year) and $118.1m (+10% year-on-year), versus analyst estimates of $199m and $115m, respectively. The former was driven by its Lutonix drug-eluting balloon, while the latter was helped by the surgical sealant contribution from Neomend, which Bard acquired last year (, 24 October 2012).


Related Content

Legal News In Brief





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts